Immatics Presents IMA401 Clinical Trial Data at ASCO Meeting

Immatics announced the presentation of extended data from the ongoing Phase 1 clinical trial evaluating its TCR bispecific candidate IMA401 targeting MAGEA4/8 in heavily pretreated patients with solid tumors, including head and neck cancer and lung cancer, in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology, ASCO, in Chicago, IL, USA. Results from the Phase 1 study are being published simultaneously in Nature Medicine. Key data: IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer; In head and neck cancer, IMA401 treatment at recommended Phase 2 dose with or without pembrolizumab resulted in a 29% confirmed ORR, 64% DCR and mDOR of 8.8 months; all responders achieved deep responses with 60-100% tumor reduction; IMA401 MAGEA4/8 TCR bispecific demonstrated favorable tolerability at RP2D with or without pembrolizumab, suggesting its potential for broad combinability; IMA401 data will be presented in an oral presentation at the 2026 ASCO Annual Meeting and published simultaneously in Nature Medicine; The data support Immatics' strategy to combine IMA401 with IMA402 in lung cancer and potentially other indications, where the combined target prevalence supports broad patient coverage and potential synergistic activity; the IMA401/IMA402 combination cohort is now enrolling at multiple clinical trial sites, with first data expected in 2027